ConductScience.org, home

Paper39401495

Immunotherapy-Based Strategies for Treatment of Type 1 Diabetes.

Jacobsen LM and 1 other. Horm Res Paediatr, 2025. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Immunotherapy-Based Strategies for Treatment of Type 1 Diabetes. Papers, record 39401495. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39401495

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immunotherapy-Based Strategies for Treatment of Type 1 Diabetes.
PubMed
Journal
Horm Res Paediatr
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2026-05-01
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Jacobsen LMLaura M
2Schatz DDesmond

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Diabetes Mellitus, Type 1Major topic
ImmunotherapyMajor topic
Antibodies, Monoclonal, HumanizedMajor topic
Humans
Adolescent
Insulin

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
K08 DK128628NIDDK NIH HHSUnited StatesK08DK128628PubMed and NIHNIH RePORTER
P01 AI042288NIAID NIH HHSUnited StatesP01AI042288PubMed and NIHNIH RePORTER

Download CSV of grants

References51

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118779574IL-21 signaling is critical for the development of type I diabetes in the NOD mouse.Proc Natl Acad Sci U S A2008https://conductscience.org/library/papers/18779574PubMed
233662334Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Diabetes Endocrinol2021https://conductscience.org/library/papers/33662334PubMed
321714999Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.Lancet2011https://conductscience.org/library/papers/21714999PubMed
423562090Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.Lancet2013https://conductscience.org/library/papers/23562090PubMed
524026563B-lymphocyte depletion with rituximab and β-cell function: two-year results.Diabetes Care2014https://conductscience.org/library/papers/24026563PubMed
614693724C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.Diabetes2004https://conductscience.org/library/papers/14693724PubMed
729925930Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes.Genes Immun2019https://conductscience.org/library/papers/29925930PubMed
819940299Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.N Engl J Med2009https://conductscience.org/library/papers/19940299PubMed
936566274
A randomized trial of oral gamma aminobutyric acid (GABA) or the combination of GABA with glutamic acid decarboxylase (GAD) on pancreatic islet endocrine function in children with newly diagnosed type 1 diabetes.
Nat Commun2022https://conductscience.org/library/papers/36566274PubMed
1038055252Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes.N Engl J Med2023https://conductscience.org/library/papers/38055252PubMed
1124089509Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial.Diabetes2014https://conductscience.org/library/papers/24089509PubMed
1231180194An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.N Engl J Med2019https://conductscience.org/library/papers/31180194PubMed
1333469446New Insights Into the Role of Autoreactive CD8 T Cells and Cytokines in Human Type 1 Diabetes.Front Endocrinol (Lausanne)2020https://conductscience.org/library/papers/33469446PubMed
1415855569Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.Diabetes Care2005https://conductscience.org/library/papers/15855569PubMed
1537861217Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.N Engl J Med2023https://conductscience.org/library/papers/37861217PubMed
1630967424Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.Diabetes2019https://conductscience.org/library/papers/30967424PubMed
1732704564A quantitative measure of treatment response in recent-onset type 1 diabetes.Endocrinol Diabetes Metab2020https://conductscience.org/library/papers/32704564PubMed
1839079992Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial.Nat Med2024https://conductscience.org/library/papers/39079992PubMed
1924296850Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.Diabetes Care2014https://conductscience.org/library/papers/24296850PubMed
2030012675Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.Diabetes Care2018https://conductscience.org/library/papers/30012675PubMed

See all 51 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42851930Artificial intelligence-driven therapeutics for disease modification in type 1 diabetes: a digital public health and clinical translation framework.Front Public Health2026https://conductscience.org/library/papers/42851930PubMed
42589969Reducing Diabetic Ketoacidosis in Pediatric Type 1 Diabetes: The Impact of Screening Programs and Early Disease-Modifying Treatment.J Clin Med2026https://conductscience.org/library/papers/42589969PubMed
41007060Advances in Childhood Diabetes.Children (Basel)2025https://conductscience.org/library/papers/41007060PubMed
39606229Small-molecule inhibitors of the CD40-CD40L costimulatory interaction are effective in pancreatic islet transplantation and prevention of type 1 diabetes models.Front Immunol2024https://conductscience.org/library/papers/39606229PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39401495

GET https://conductscience.org/api/papers/v1/39401495/references?page=2